Abstract 1623: Response and skin toxicity related protein signature in late stage melanoma patients after anti-PD-1 treatment

2021 ◽  
Author(s):  
Jakob Vowinckel ◽  
Domenico Mallardo ◽  
Kamil Sklodowski ◽  
Martin Soste ◽  
Mariaelena Capone ◽  
...  
Keyword(s):  
Late Stage ◽  
Skin Toxicity ◽  
Related Protein ◽  
Melanoma Patients ◽  
Protein Signature

Identification of risk factors leading to a late stage diagnosis in elderly melanoma patients.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e20063-e20063
Author(s):  
Justin John Baker ◽  
Yana Wirengard ◽  
Lee Lucas ◽  
Heidi Wierman ◽  
Kathleen Fairfield
Keyword(s):  
Risk Factors ◽  
Late Stage ◽  
Late Stage Diagnosis ◽  
Melanoma Patients

Humanistic burden of disease in earlier stage metastatic (stage IIIb/c-IVM1a) versus late stage metastatic (IVM1b/c) melanoma patients in a real-world setting in the U.S.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 9561-9561
Author(s):  
Jacqueline Buchanan ◽  
Swaminathan Murugappan ◽  
Rebecca Moon ◽  
Adam Roughley ◽  
Alex Rider
Keyword(s):  
Metastatic Melanoma ◽  
Real World ◽  
Late Stage ◽  
Well Being ◽  
Primary Diagnosis ◽  
Cross Sectional Survey ◽  
Health States ◽  
Cross Sectional ◽  
Caregiver Support ◽  
Melanoma Patients

9561 Background: To assess melanoma specific health-related quality of life (HRQoL) and health states in patients with earlier stage metastatic (IIIb/c-IVM1a) versus late stage metastatic (IVM1b/c) melanoma. Methods: Data were collected from the Adelphi Real World Advanced Melanoma Disease-Specific Programme, a cross-sectional survey of 112 physicians and their patients (N = 666). Data were collected between March and July 2016 in the US. A subset of 183 patients completed the Functional Assessment of Cancer Therapy Melanoma (FACT-M) and EuroQol-5D (EQ-5D) one time. Patients were classified by stage of melanoma at time of consultation. Descriptive analyses of HRQoL scores between earlier and late stage metastatic melanoma were assessed using Mann-Whitney U tests. Results: The mean age of the earlier stage and late stage metastatic patients was 62 and 64 respectively. More earlier stage metastatic patients had an ECOG status of 0 or 1 versus late stage metastatic patients (85%, 75% respectively). A total of 31% of late stage metastatic patients required caregiver support and had a median time since primary diagnosis of 5.0 months whereas earlier stage metastatic patients reported 14% and 5.2 months respectively. Patients with earlier stage metastatic melanoma had better mean EQ-5D index scores versus late stage metastatic melanoma patients (0.81 (n = 84), 0.76 (n = 93); p = 0.0103). Higher scores indicating better HRQoL were observed between earlier stage metastatic versus late stage metastatic melanoma patients for the FACT-M (120.7 (n = 81), 107.4 (n = 91); p = 0.0017) and subscales (except Social Well Being). Clinically meaningful differences between groups using published minimal important differences (MIDs) were observed in in 6/7 FACT-M subscales and EQ-5D VAS. Conclusions: Differences in HRQoL and health states were observed between earlier stage metastatic and late stage metastatic melanoma populations, highlighting the detrimental effect of developing metastatic disease. These results suggest that treatments that delay progression of the disease are important to conserve patients HRQoL

Abstract 1233: Immunological biomarkers predicting survival in late-stage melanoma patients.

2013 ◽  
Author(s):  
Alexander Martens ◽  
Henning Zelba ◽  
Benjamin Weide ◽  
Claus Garbe ◽  
Graham P. Pawelec
Keyword(s):  
Late Stage ◽  
Melanoma Patients

scholarly journals Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib

2016 ◽  
Vol 1 ◽  
pp. 52-56 ◽  
Author(s):  
Elzbieta Nowara ◽  
Joanna Huszno ◽  
Grzegorz Slomian ◽  
Jaroslaw Nieckula
Keyword(s):  
Cutaneous Melanoma ◽  
Skin Toxicity ◽  
Melanoma Patients

Long-term effects of laser-imiquimod combination in the treatment of late-stage melanoma patients

2012 ◽  
Author(s):  
Mark F. Naylor ◽  
Henry Le ◽  
Xiaosong Li ◽  
Robert E. Nordquist ◽  
Tomas Hode ◽  
...  
Keyword(s):  
Late Stage ◽  
Long Term Effects ◽  
Melanoma Patients

Hypercalcaemia in melanoma patients associated with increased levels of parathyroid hormone-related protein

1999 ◽  
Vol 9 (1) ◽  
pp. 69-74 ◽  
Author(s):  
T. Kageshita ◽  
T. Matsui ◽  
S. Hirai ◽  
Y. Fukuda ◽  
T. Ono
Keyword(s):  
Parathyroid Hormone ◽  
Related Protein ◽  
Parathyroid Hormone Related Protein ◽  
Melanoma Patients

scholarly journals Anti-Tyrosinase-Related Protein-2 Immune Response in Vitiligo Patients and Melanoma Patients Receiving Active-Specific Immunotherapy

1998 ◽  
Vol 111 (6) ◽  
pp. 1034-1039 ◽  
Author(s):  
Tetsuro Okamoto ◽  
Shigeyuki Fujii ◽  
Sharon K.S. Huang ◽  
Dave S.B. Hoon ◽  
Reiko F. Irie ◽  
...  
Keyword(s):  
Immune Response ◽  
Specific Immunotherapy ◽  
Related Protein ◽  
Active Specific Immunotherapy ◽  
Melanoma Patients ◽  
Tyrosinase Related Protein
Sign in / Sign up

Export Citation Format

Share Document